1. 1384PDPembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. (23rd October 2018) Authors: Middleton, G; Brock, K; Summers, Y; Connibear, J; Shah, R; Ottensmeier, C; Shaw, P; Ming-Lee, S; Popat, S; Barrie, C; Barone, G; Mant, R; Savage, J S; Billingham, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 646PEGFR amplification (amp) and survival in the REAL-3 trial. (23rd October 2018) Authors: Smyth, E; Kouvelakis, K; Cunningham, D; Hahne, J C; Peckitt, C; Vlachogiannis, G; Watkins, D; Rao, S; Starling, N; Wilson, S H; Waddell, T S; Okines, A; Crosby, T; Mansoor, W; Wadsley, J; Middleton, G; Wotherspoon, A; Chau, I; Valeri, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Mechanisms of immunogenicity in colorectal cancer. Issue 10 (19th June 2019) Authors: Sillo, T O; Beggs, A D; Morton, D G; Middleton, G Journal: British journal of surgery Issue: Volume 106:Issue 10(2019) Page Start: 1283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗